JSMD194

Overview

JSMD194 (formerly LY3039478) is a small molecule Gamma-Secretase Inhibitor being investigated in clinical trials in patients with T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma and multiple myeloma.

SparkCures ID 313
Developed By Eli Lilly and Company
Generic Name JSMD194
Additional Names LY3039478
Treatment Classifications
  • Gamma-Secretase Inhibitor

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.